Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This exploratory pilot study was an open-label, crossover, single-center and non-randomized
clinical trial designed to compare the effect of the standardly employed doses of allopurinol
(400 mg/day) and febuxostat (80 mg/day) on the urinary 2,8-dihydroxyadenine (DHA) excretion
in patients with adenine phosphoribosyltransferase (APRT) deficiency.
Phase:
Phase 4
Details
Lead Sponsor:
Landspitali University Hospital
Collaborators:
Mayo Clinic National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)